A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of orally-administered CR845 in patients with
osteoarthritis (OA) of the hip or knee. The study drug is being tested to reduce OA pain, and
will be taken twice a day for two weeks, with four different doses (strengths) being tested.
From screening period to follow up examination, the study is expected to last for up to 38
days per participant.